Acceleron Pharma, Inc., A Wholly-owned Subsidiary Of Merck & Co., Inc., Rahway, Nj Usa
Clinical trials sponsored by Acceleron Pharma, Inc., A Wholly-owned Subsidiary Of Merck & Co., Inc., Rahway, Nj Usa, explained in plain language.
-
New hope for severe lung disease: drug delays death and hospitalization
Disease control CompletedThis study tested a drug called sotatercept in 173 people with severe pulmonary arterial hypertension (PAH), a serious lung condition that makes the heart work too hard. Participants received either the drug or a placebo on top of their usual treatments. The goal was to see if th…
Phase: PHASE3 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug shows promise for Hard-to-Treat lung condition in heart failure
Disease control CompletedThis Phase 2 trial tested a drug called sotatercept in 164 adults with a type of high blood pressure in the lungs caused by heart failure. The study compared sotatercept to a placebo to see if it could improve blood flow and walking distance. The goal is to find a better treatmen…
Phase: PHASE2 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC